Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new drugs: Ketotifen Fumarate Eye Drops and Calcium Gluconate Injection. These approvals mark significant advancements in the company’s product offerings, enhancing its position in the pharmaceutical market by expanding its portfolio of ophthalmic and treatment drugs.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a company operating in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating ophthalmic preparations and other medical treatments, with a market focus on China.
Average Trading Volume: 13,312,394
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.62B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.